Acute-on-chronic liver failure.

Acute-on-chronic liver failure acute decompensation high short-term mortality liver cirrhosis organ failure

Journal

Clinical medicine (London, England)
ISSN: 1473-4893
Titre abrégé: Clin Med (Lond)
Pays: England
ID NLM: 101092853

Informations de publication

Date de publication:
09 2020
Historique:
entrez: 16 9 2020
pubmed: 17 9 2020
medline: 15 5 2021
Statut: ppublish

Résumé

Acute-on-chronic liver failure (ACLF) is a recently recognised and defined syndrome seen in patients with liver cirrhosis and carries a high short-term mortality in excess of 15% at 28 days. ACLF is defined by organ failures (OFs) and is distinct from simple 'acute decompensation' (AD) of cirrhosis. OFs involve the liver, kidney, brain, coagulation, respiratory system and the circulation, and are defined by the European Association for the Study of the Liver Chronic Liver Failure Consortium (CLIF-C) OF score. The central pathophysiological mechanism in the development of ACLF is intense systemic inflammation, which distinguishes this syndrome from AD. The most frequent precipitating event of ACLF in the western world is bacterial infection and active alcohol intake, whereas hepatitis B flare followed by sepsis and active alcohol intake are the common precipitating events in the east. In about 40% patients with ACLF, however, no precipitating event is found. The course of ACLF is dynamic and reversible, so early identification and early initiation of supportive therapy is of utmost importance. Unfortunately, to date, there is no known specific therapy for ACLF except for liver transplantation, so the treatment revolves around institution of early organ support. Most of the patients will have a clear prognosis between 3-7 days of hospitalisation. CLIF-C ACLF score is the best available prognostic score in patients with ACLF.

Identifiants

pubmed: 32934045
pii: 20/5/501
doi: 10.7861/clinmed.2020-0631
pmc: PMC7539713
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

501-504

Informations de copyright

© Royal College of Physicians 2020. All rights reserved.

Références

J Hepatol. 2018 Aug;69(2):318-324
pubmed: 29524528
Hepatology. 2015 Jul;62(1):243-52
pubmed: 25877702
N Engl J Med. 2009 Sep 24;361(13):1279-90
pubmed: 19776409
J Hepatol. 2014 Nov;61(5):1038-47
pubmed: 24950482
Sci Rep. 2016 May 05;6:25487
pubmed: 27146801
Hepatology. 2019 May;69(5):2150-2163
pubmed: 30615211
Gastroenterology. 2012 Apr;142(4):782-789.e3
pubmed: 22248661
Gut. 2018 Dec;67(12):2181-2191
pubmed: 28928275
J Hepatol. 2020 Jun 16;:
pubmed: 32561318
Clin Gastroenterol Hepatol. 2018 Nov;16(11):1792-1800.e3
pubmed: 29391267
J Hepatol. 2019 Apr;70(4):639-647
pubmed: 30590100
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Hepatol Int. 2019 Jul;13(4):353-390
pubmed: 31172417
Gastroenterology. 2019 Apr;156(5):1381-1391.e3
pubmed: 30576643
Gut. 2018 Oct;67(10):1870-1880
pubmed: 28847867
J Hepatol. 2020 Apr 24;:
pubmed: 32339602
Hepatology. 2016 Oct;64(4):1249-64
pubmed: 27483394
Liver Transpl. 2018 Mar;24(3):380-393
pubmed: 29171941
J Hepatol. 2017 Oct;67(4):708-715
pubmed: 28645736
Hepatology. 2014 Jul;60(1):250-6
pubmed: 24677131

Auteurs

Rahul Kumar (R)

Changi General Hospital, Singapore.

Gautam Mehta (G)

University College London Medical School, London, UK and Foundation for Liver Research, London, UK.

Rajiv Jalan (R)

University College London Medical School, London, UK r.jalan@ucl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH